the invention is also directed to pharmaceutical compositions comprising the compounds of formula i and to use of the compounds in the treatment of diseases associated with lrrk2 such as neurodegenerative diseases including parkinson 39 s disease or alzheimer 39 s disease cancer crohn 39 s disease or leprosy application_number US 201415104659 A description typically a compound of the invention is administered in an amount effective to treat a condition as described herein the compounds of the invention are administered by any suitable route in the form of a pharmaceutical composition adapted to such a route and in a dose effective for the treatment intended therapeutically effective doses of the compounds required to treat the progress of the medical condition are readily ascertained by one of ordinary skill in the art using preclinical and clinical approaches familiar to the medicinal arts the term u201c treating u201d as used herein unless otherwise indicated means reversing alleviating inhibiting the progress of or preventing the disorder or condition to which such term applies or one or more symptoms of such disorder or condition the term u201c treatment u201d as used herein unless otherwise indicated refers to the act of treating as u201c treating u201d is defined immediately above the term u201c treating u201d also includes adjuvant and neo adjuvant treatment of a subject the compounds of the invention may be administered orally oral administration may involve swallowing so that the compound enters the gastrointestinal tract or buccal or sublingual administration may be employed by which the.